Johnson & Johnson stock edges lower as insider sale comes near 52-week high

Johnson & Johnson (US4781601046) stock is trading close to its 52-week high as of September 4, 2026, even as an executive stock sale and updated earnings expectations prompt investors to reassess the healthcare giant's valuation and dividend strength.

Insider sale near 52-week high

According to an insider trading report by Investing.com dated September 4, 2026, Johnson & Johnson executive vice president Timothy Schmid sold approximately USD 9.2 million in company stock as shares traded close to their 52-week high of USD 281.07.

The same report notes that Johnson & Johnson shares are up 59% over the past year, underlining how strongly the stock has performed compared with many healthcare peers over the last twelve months.

Dividend and earnings outlook

Income investors continue to focus on Johnson & Johnson's dividend. As highlighted in a feature on dividend stocks published on September 4, 2026, Johnson & Johnson recently paid a quarterly dividend of USD 1.34 per share on June 9, 2026 and plans to pay another USD 1.34 per share on September 8, 2026, maintaining a consistent payout pattern.

On the earnings side, a Zacks analysis dated September 4, 2026 states that excluding the impact of the loss of exclusivity for Stelara, Johnson & Johnson's total revenue grew in a double-digit range in both the first and second quarters of 2026, compared with mid-single-digit growth including Stelara.

The same Zacks overview reports that sales in the Abiomed business within the MedTech segment declined 2% in the second quarter of 2026 as procedure volumes slowed following changes in Impella device usage after a recent United Kingdom clinical trial raised questions about the device's benefit in certain high-risk procedures.

Analyst expectations have also inched higher. The Zacks Consensus Estimate for Johnson & Johnson's 2026 earnings per share has risen from USD 11.58 to USD 11.59 over the past 60 days, while the consensus for 2027 has increased from USD 12.65 to USD 12.80, signaling modest but positive revisions to the long-term outlook.

Going by valuation metrics cited in the same analysis, Johnson & Johnson shares currently trade at about 21.86 times forward earnings, compared with around 18.55 times for the broader industry, indicating that the stock commands a premium multiple relative to many healthcare peers.

Trading on Tradegate offers DACH reference

For investors in German-speaking markets, Johnson & Johnson is also available on Tradegate. A Tradegate quote overview compiled by MarketScreener and accessed on September 4, 2026 shows Johnson & Johnson trading at EUR 239.45, with a 5-day change of 0.80% and a year-to-date change of 2.48%, providing a DACH-region reference price in euros.

The same MarketScreener data confirms that this Tradegate quotation reflects the European secondary trading line for Johnson & Johnson, complementing the primary listing on the New York Stock Exchange under the ticker JNJ.

Key product: Stelara and segment trends

Johnson & Johnson's Innovative Medicines segment has been shaped in recent years by its immunology drug Stelara, a major product used to treat conditions such as psoriasis and Crohn's disease. The Zacks analysis dated September 4, 2026 notes that the loss of exclusivity for Stelara negatively impacted growth in this segment by 10.4% in 2025 and by 8.4% in the first half of 2026.

Excluding Stelara, however, Johnson & Johnson's top line grew in a double-digit range in both the first and second quarters of 2026, highlighting how newer therapies and other portfolio components are offsetting the drag from patent expirations.

Stock price context and investor perspective

Intraday data from finanzen.ch for the New York trading session on September 4, 2026 shows Johnson & Johnson shares at USD 275.69, down 1.0% compared with the previous close, with the stock trading between an opening level of USD 275.13 and moves that kept it close to its recent 52-week high of USD 281.07.

For investors, the combination of a roughly 59% share price increase over the past year, a forward earnings multiple of 21.86 compared with 18.55 for the industry, and a stable dividend of USD 1.34 per share scheduled for September 8, 2026 paints the picture of a healthcare blue chip that is priced at a premium but continues to generate cash flows for dividends while navigating product-specific headwinds.